PURCHASE, NY, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued inducement awards to three new...
SYDNEY, Australia and NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pancreatic ductal adenocarcinoma (PDAC), which accounts for >90% of pancreatic tumors, is one of the most lethal malignancies and...
EnGeneIC has reported that its second-generation Covid-19 EnGeneIC Dream Vector (EDV) vaccine offers protection against all variants of the SARS-CoV-2 virus in clinical trials.
SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The world’s first COVID-19 vaccine to offer immunity against all variants is one step closer.
Sciwind Biosciences announced last night that it signed an expansive license agreement with Sanofi to develop and commercialize Sanofi’s long-lasting glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. According to Sciwind, the lead candidate is currently under preclinical development.
SYDNEY and NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- EnGeneIC Limited, an Australian, Sydney-based biotechnology company, has developed a globally unique nanocellular technology that in pre-clinical animal studies has been shown to stimulate a broad and powerful anti-COVID-19 immune response and also neutralises the known mutant COVID-19 viruses of concern, particularly the delta variant.